PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Ann Neurol. Author manuscript; available in PMC 2012 October 1.
Published in final edited form as:
PMCID: PMC3205432
NIHMSID: NIHMS286092

Greater effect of stroke thrombolysis in the presence of arterial obstruction

Deidre A De Silva, MBBS, MRCP, FAMS, Leonid Churilov, PhD, Jean-Marc Olivot, MD, PhD, Soren Christensen, MD, PhD, Maarten G Lansberg, MD, PhD, Michael Mlynash, MD, MS, Bruce CV Campbell, MBBS, BMedSc, FRACP, Patricia Desmond, MSc MD FRANZCR, Matus Straka, PhD, Roland Bammer, PhD, Gregory W Albers, MD, Stephen M Davis, MD, FRACP, and Geoffrey A Donnan, MD, FRACP, on behalf of the EPITHET-DEFUSE Investigators

Abstract

Objective

Recanalization of arterial obstruction is associated with improved clinical outcomes. There are no controlled data demonstrating whether arterial obstruction status predicts the treatment effect of intravenous (IV) tissue plasminogen activator (tPA). We aimed to determine if the presence of arterial obstruction improves the treatment effect of IV tPA over placebo in attenuating infarct growth.

Methods

We analyzed 175 ischemic stroke patients treated in the 3-6 hour time window from the EPITHET trial (randomized to IV tPA or placebo) and DEFUSE study (all treated with IV tPA). Infarct growth was calculated as the difference between baseline DWI and final T2 lesion volumes. Baseline arterial obstruction of large intracranial arteries was graded on magnetic resonance angiography (MRA).

Results

Among the 116 patients with adequate baseline MRA and final lesion assessment, 72 had arterial obstruction (48 tPA, 24 placebo) and 44 no arterial obstruction (33 tPA, 11 placebo). Infarct growth was lower in the tPA than placebo group (median difference 26mL, 95% CI 1 to 50) in patients with arterial obstruction, but was similar in patients with no arterial obstruction (median difference 5mL, 95%CI -3 to 9). Infarct growth attenuation with tPA over placebo treatment was greater among patients with arterial obstruction than those without arterial obstruction by a median of 32 mL (95%CI 21to 43, p<0.001).

Interpretation

The treatment effect of IV tPA over placebo was greater with baseline arterial obstruction, supporting arterial obstruction status as a consideration in selecting patients more likely to benefit from IV thrombolysis.

Introduction

The aim of stroke thrombolysis is recanalization of an arterial obstruction with subsequent reperfusion leading to infarct growth attenuation with the ultimate goal of better clinical outcomes. Intravenous (IV) stroke thrombolysis has a narrow therapeutic window with decreasing benefit and escalating risk with increasing time from onset. 1 Attempts to widen the therapeutic window have employed selection criteria that include profiles with greater potential for benefit and exclude those with increased risk of symptomatic intracerebral hemorrhage (sICH).

Arterial obstruction has been proposed as a selection criterion for stroke thrombolysis, supported by data showing recanalization with IV tissue plasminogen activator (tPA) improves clinical outcomes. 2-3 Post-hoc Desmoteplase In Acute Ischemic Stroke (DIAS) II trial data demonstrated a trend for clinical benefit with IV desmoteplase in a subgroup with arterial obstruction. 4 Patient selection based on arterial obstruction was used in the intra-arterial Prolyse in Acute Cerebral Thromboembolism (PROACT) II study which included patients with high grade stenosis/ occlusion of the middle cerebral artery (MCA) M1 or M2 segment), 5 and is currently being employed in the DIAS III and IV trials which include those with high grade stenosis or occlusion of proximal arteries. 6-7

The presence of arterial obstruction has been shown to result in larger infarct growth and poorer clinical outcomes in patients not treated with thrombolysis 8-9 and in cohorts including patients who did and did not undergo thrombolytic treatments. 10-11 There are no published data demonstrating that arterial obstruction influences the impact of IV tPA versus placebo. We aimed to test the hypothesis that the presence of arterial obstruction improves the treatment benefit of IV tPA over placebo in terms of infarct growth attenuation.

Methods

This is a post-hoc study including pooled data from the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and Diffusion and perfusion imaging Evaluation For Understanding Stroke Evolution (DEFUSE) study. EPITHET is a multicenter, randomized, double blinded, controlled trial of IV tPA versus placebo in the 3-6 hour window. 12 The DEFUSE study is a multicenter prospective cohort treated with IV tPA also in the 3-6 hour window. 13 Informed consent was obtained from all participants in EPITHET and DEFUSE, both of which were approved by the ethics committees of the individual participating centers.

In both EPITHET and DEFUSE, patients underwent baseline magnetic resonance imaging (MRI) prior to treatment, including magnetic resonance angiography (MRA), diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) sequences. Final lesion was assessed on follow-up MRI at day 30 in DEFUSE and day 90 in EPITHET, using T2-weighted sequences.

We performed uniform standardized assessment of arterial obstruction for the EPITHET and DEFUSE cohorts by consensus of three investigators masked to clinical factors. Arterial obstruction was graded as no obstruction, partial obstruction or complete occlusion of the artery corresponding to the acute infarction. 3 For these analyses, arterial obstruction was defined as partial obstruction and completed occlusion.

Baseline DWI, baseline PWI and final T2 lesions were assessed using the original EPITHET and DEFUSE protocols. 12-13 PWI lesions were defined as Tmax delay of 2 seconds or more from Tmax maps generated using deconvolution algorithms using arterial input function selected from the contralateral middle cerebral artery. 12-13 Mismatch was defined as a profile with PWI lesion larger than DWI lesion volume by 20% and at least 10mL, as per the original EPITHET and DEFUSE definitions. Infarct growth was the absolute difference between final T2 lesion and baseline DWI lesion volumes. Functional outcome was assessed at day 90 using the modified Rankin score (mRS) with good outcome defined as mRS 0-2.

We compared the baseline characteristics based on arterial obstruction status using the Pearson's Chi-square and Wilcoxon-Mann-Whitney rank-sum tests. The difference in infarct growth between treatment arms for subgroups with and without arterial obstruction was estimated by Hodges-Lehman nonparametric shift estimator. A median regression model with treatment-by-obstruction status interaction term was employed to determine the influence of arterial obstruction on infarct growth attenuation between treatment arms.

Results

There were 101 patients in EPITHET and 74 in DEFUSE. Of these 175 patients, 154 had adequate MRA data (MRA not performed for 1 and of poor quality for 14). Among these, the final lesion could be assessed for 116 patients (final MRI not performed for 37 and of poor quality for 1). In this 116 cohort with data analyzed, 72 had baseline arterial obstruction (48 tPA, 24 placebo) and 44 no obstruction (33 tPA, 11 placebo). Among the 72 with arterial obstruction, 45 had complete occlusion and 27 partial obstruction. The site of obstruction was the internal carotid artery for 22, MCA M1 for 43, M2 for 4 and posterior cerebral artery for 3.

Table 1 shows the comparison of baseline characteristics based on arterial obstruction status. Patients with arterial obstruction were younger than those with no obstruction [median age 70 (IQR 58 to 78) vs 76 (IQR 71 to 83) years, p=0.004]. As expected, those with arterial obstruction had a higher National Institutes of Health Stroke Scale (NIHSS) score [median 14 (IQR 9 to 17) vs 9 (IQR 7 to 14) mL, p=0.001], larger DWI [median 18.5 (IQR 5.0 to 39.0) vs 9.9 (IQR 3.0 to 18.30) mL, p=0.017], PWI [median 134.8 (IQR 63.5 to 228.4) vs 57.9 (IQR 5.0 to 95.5) mL, p<0.001] and mismatch [median 102.0 (IQR 36.0 to 195.5) vs 35.8 (IQR 0 to 75.0) mL, p<0.001] volumes as well as higher prevalence of the mismatch profile (84% vs 57%, p=0.003).

Table 1
Baseline characteristics of patients by baseline arterial obstruction status

The treatment effect of infarct growth attenuation was greater among patients with arterial obstruction than those with no arterial obstruction on MRA. Among those with arterial obstruction, there was less infarct growth in the tPA compared to placebo arms by a median difference of 26 mL (95% CI 1 to 50, p=0.03) (Table 2), as estimated by Hodges-Lehman nonparametric shift estimator. Infarct growth was similar between placebo and tPA arms in the patients with no arterial obstruction (median difference 5mL 95% CI -3 to 9, p=0.22). Using median regression models, the median difference in infarct growth attenuation with tPA over placebo between patients with and without arterial obstruction was 32 mL (95% CI 21 to 43, p<0.001). This remained significant with a median difference of 33 mL (95% CI 22 to 43, p<0.001) with adjustment for age.

Table 2
Median infarct growth in mL (95% CI) by baseline arterial status and treatment arm

Among the 24 patients who had no arterial obstruction but had the mismatch profile, infarct growth appeared attenuated in the tPA group (median -1.94 IQR -6.36 to 5.72 mL) compared to the placebo groups (median 5.24 IQR -2.90 to 10.31 mL) but the difference was not statistically significant (Hodges-Lehmann median difference -4.86 95% CI -13.56 to 6.33 mL, p=0.320). Infarct growth was significantly lower among patients who achieved good functional outcome (median 0 IQR -2.63 to 5.15 mL) compared to those who did not (17.70 IQR 0.68 to 63.34 mL) by a Hodges-Lehmann median difference of -18.35mL (95% CI -31.90 to -8.40mL, p<0.001). Using logistic regression, for 1mL of absolute infarct growth, the OR of good functional outcome was 0.97 (95% CI 0.95 to 0.98). Among patients without arterial obstruction, good functional outcome occurred in 66% (25) treated with tPA and 42% (5) in the placebo arm (OR 2.69, 95%CI 0.59 to 12.85). Among patients with arterial obstruction good functional outcomes occurred in 43% (32) treated with tPA and 34% (10) in the placebo arm (OR 1.44, 95%CI 0.55 to 3.98).

Discussion

The beneficial effect of IV tPA over placebo on infarct growth attenuation was significantly greater in patients with arterial obstruction than those with no arterial obstruction. Potential reasons for this finding include the larger hypoperfusion and diffusion-perfusion mismatch lesions among patients with arterial obstruction that are potentially salvageable with recanalization. Alternatively, spontaneous recanalization may have occurred with no potential for further infarct growth. The infarct growth difference of a median 32 mL is sizeable. This difference is expected to influence the likelihood of good functional outcome which was reduced by 3% for every 1mL of absolute infarct growth.

This study's data support the concept of arterial obstruction as a selection criterion to identify patients more likely to benefit from IV tPA, particularly beyond the 3 hour time window. Assessment of arterial obstruction status using MRA may be easier and faster to ascertain than the presence of ischemic penumbra delineated by diffusion-perfusion mismatch, another candidate selection criterion for stroke thrombolysis. This is particularly important with the time pressure to minimize the duration from stroke onset to initiation of thrombolysis. One strength of diffusion-perfusion mismatch over arterial obstruction status as a selection criterion is that features of the ischemic penumbra such as the malignant profile can predict risk of sICH complications. 13 Within 3 hours of stroke onset, arterial obstruction status may not influence the treatment effect of IV tPA and its assessment may unnecessarily delay time to thrombolysis.

The presence of arterial obstruction does not equate to that of an ischemic penumbra. 9, 14 This is evidenced by our data showing that 16% with arterial obstruction did not have a mismatch profile. Arterial obstruction may occur without any corresponding tissue hypoperfusion due to alternative arterial supply via collaterals and communicating arteries, early completed infarct growth into the ischemic penumbra or recanalization of a tandem arterial obstruction. 9, 14 On the other hand, tissue hypoperfusion may be evident despite no obstruction of large arteries due to involvement of arteries too small to be imaged with MRA, partial spontaneous recanalization or the no-reflow phenomenon. 9, 14 In this study, among patients with no arterial obstruction, 57% had a mismatch profile with a median mismatch volume of 35.8 mL (IQR 0 to 75.0). Among patients with the mismatch profile but no large arterial obstruction, tPA appeared to have some beneficial effect in attenuating infarct growth compared to placebo, but these findings were underpowered and not statistically significant. Thus, larger studies are required to verify this. There are currently no published data comparing arterial obstruction and diffusion-perfusion mismatch as selection criteria for stroke thrombolysis. Use of the dual target selection criteria of both arterial obstruction and diffusion-perfusion mismatch has been proposed but there is a paucity of evidence for this strategy. 14

We confirm that infarct growth correlated with functional outcomes in this pooled dataset, consistent with findings from the EPITHET trial and DEFUSE study. 12-13 Although the rate of good functional outcome was higher in the tPA versus placebo arms for both groups with and without arterial obstruction, the differences were not statistically significant. This is expected as the EPITHET trial and these post-hoc analyses were not powered for clinical outcomes.

The main strengths of this study were the placebo control arm which allows for assessment of treatment effect, adequate sample size with pooling of EPITHET and DEFUSE data, and uniform assessment of arterial obstruction status. There were some limitations. First, infarct growth attenuation is a surrogate outcome measure. Although infarct growth is strongly correlated with clinical outcomes, 12 these findings need to be confirmed with clinical outcomes. Second, MRA has its own limitations as a modality for assessment of arterial obstruction, including overestimation of degree of obstruction and poor resolution for smaller arteries particularly as it was not performed with contrast. Third, in view of the post-hoc nature of the analyses, these findings should be interpreted with caution and replicated in other studies.

In the pooled EPITHET and DEFUSE cohort, the treatment benefit of IV tPA over placebo using an imaging surrogate of infarct growth attenuation was greater in patients with arterial obstruction on MRA versus those with no arterial obstruction. Thus, arterial obstruction status might provide additional or complementary information in treatment selection for IV tPA, particularly in the wider time windows.

Acknowledgments

Funding support from:

National Health and Medical Research Council, Australia

National Stroke Foundation, Australia

Heart Foundation of Australia. Australia

National Institute on Neurological Disorders and Stroke

tPA was supplied at no charge by Genentech and Boehringer Ingelheim

Contributor Information

Deidre A De Silva, Department of Neurology, Singapore General Hospital campus, National Neuroscience Institute, Singapore.

Leonid Churilov, Florey Neuroscience Institutes (National Stroke Research Institute) and Department of Mathematics and Statistics, University of Melbourne, Australia.

Jean-Marc Olivot, Stanford Stroke Center, Stanford University, USA.

Soren Christensen, Departments of Neurology and Radiology, The Royal Melbourne Hospital, University of Melbourne, Australia.

Maarten G Lansberg, Stanford Stroke Center, Stanford University, USA.

Michael Mlynash, Stanford Stroke Center, Stanford University, USA.

Bruce CV Campbell, Department of Neurology, Royal Melbourne Hospital, University of Melbourne, Australia.

Patricia Desmond, Department of Radiology, Royal Melbourne Hospital, University of Melbourne, Australia.

Matus Straka, Stanford Stroke Center, Stanford University, USA.

Roland Bammer, Stanford Stroke Center, Stanford University, USA.

Gregory W Albers, Stanford Stroke Center, Stanford University, USA.

Stephen M Davis, Department of Neurology, Royal Melbourne Hospital and University of Melbourne, Australia.

Geoffrey A Donnan, Florey Neuroscience Institutes, Austin Health, University of Melbourne, Australia.

References

1. Lansberg MG, Schrooten M, Bluhmki E, et al. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke. 2009;40:2079–2084. [PMC free article] [PubMed]
2. De Silva DA, Fink JN, Christensen S, et al. Assessing reperfusion and recanalization as markers of clinical outcomes after intravenous thrombolysis in the echoplanar imaging thrombolytic evaluation trial (EPITHET) Stroke. 2009;40:2872–2874. [PubMed]
3. Marks MP, Olivot JM, Kemp S, et al. Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the DEFUSE study. Radiology. 2008;249:614–623. [PubMed]
4. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8:141–150. [PMC free article] [PubMed]
5. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003–2011. [PubMed]
6. DIAS-3 Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke. [Accessed 22 March 2011]; http://www.strokecenter.org/trials/trialdetail.aspx?tid=914.
7. DIAS-4 Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke. [Accessed 22 March 2011]; http://www.strokecenter.org/trials/TrialDetail.aspx?tid=961.
8. Liu Y, Karonen JO, Vanninen RL, et al. Acute ischemic stroke: predictive value of 2D phase-contrast MR angiography--serial study with combined diffusion and perfusion MR imaging. Radiology. 2004;231:517–527. [PubMed]
9. Barber PA, Davis SM, Darby DG, et al. Absent middle cerebral artery flow predicts the presence and evolution of the ischemic penumbra. Neurology. 1999;52:1125–1132. [PubMed]
10. Rother J, Schellinger PD, Gass A, et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke. 2002;33:2438–2445. [PubMed]
11. Fiehler J, Knudsen K, Thomalla G, et al. Vascular occlusion sites determine differences in lesion growth from early apparent diffusion coefficient lesion to final infarct. Am J Neuroradiol. 2005;26:1056–1061. [PubMed]
12. Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299–309. [PubMed]
13. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60:508–517. [PubMed]
14. Staroselskaya IA, Chaves C, Silver B, et al. Relationship between magnetic resonance arterial patency and perfusion-diffusion mismatch in acute ischemic stroke and its potential clinical use. Arch Neurol. 2001;58:1069–1074. [PubMed]